HK Stock Market Move | Zhenjiankang Medical (02697) rises over 8% as it collaborates with Tianjin Embodied Intelligence Innovation Center to jointly build an embodied intelligence medical ecosystem. The company is deeply engaged in the minimally invasive intervention sector.
Zhenjian Health Medical (02697) rose over 8%. As of the time of writing, it has increased by 7.34%, trading at HKD 790, with a transaction volume of HKD 7.47 million.
Zhenjiankang Medical (02697) rose over 8%, and as of this report, it is up 7.34%, priced at HKD 790, with a trading volume of HKD 7.47 million.
In recent news, Zhenjiankang Medical signed a strategic cooperation framework agreement with the Tianjin Embodied Intelligence Innovation Center. Both parties will establish a long-term cooperation mechanism in the field of embodied intelligence, jointly promoting the intelligent upgrade of minimally invasive intervention diagnostics and the ecological construction of the embodied intelligence medical industry. This cooperation aims to deeply connect Zhenjiankang Medicals independent innovation and engineering capabilities in minimally invasive intervention and intraoperative navigation with the computing power, data, and ecological resources of the Tianjin Embodied Intelligence Innovation Center, which is expected to open new growth opportunities for the intelligentization of precise intervention diagnostics.
It is worth mentioning that Zhenjiankang Medical has been deeply engaged in the minimally invasive intervention sector for a long time. In June of this year, it went public on the Hong Kong Stock Exchange as "Siasun Robot & Automation's first stock in puncture surgery." It is a pioneer and leading enterprise in the research, development, and commercialization of percutaneous puncture and ablation surgeries in China. Several self-developed products have obtained Class III medical device registration certificates from the National Medical Products Administration, with the puncture surgery navigation system recognized as a domestic innovation and the microwave ablation navigation system recognized as an international innovation, creating an integrated minimally invasive diagnostic and therapeutic solution for precise localization and ablation treatment of lesions.
Related Articles

GALAXY ENT (00027) announced its interim results, with a profit attributable to shareholders of HKD 5.3 billion, an increase of 1% year-on-year.

CEB GREENTECH (01257) will distribute an interim dividend of HKD 0.029 per share on October 13.

CEB GREENTECH (01257) announced its interim results, with profit attributable to equity shareholders amounting to approximately HKD 195 million, representing a year-on-year growth of 2%.
GALAXY ENT (00027) announced its interim results, with a profit attributable to shareholders of HKD 5.3 billion, an increase of 1% year-on-year.

CEB GREENTECH (01257) will distribute an interim dividend of HKD 0.029 per share on October 13.

CEB GREENTECH (01257) announced its interim results, with profit attributable to equity shareholders amounting to approximately HKD 195 million, representing a year-on-year growth of 2%.

RECOMMEND





